Seniors Integrated Longitudinal cardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)
NCT ID: NCT06880575
Last Updated: 2025-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10139 participants
OBSERVATIONAL
2024-11-06
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Study plan to continuously enroll hospitalized elderly CHD patients across 50 centers nationwide. Using networked electronic data collection technology, standardized methods and protocols will be used to gather demographic information (such as age, gender, education level, income, etc.), clinical information (medical history, past treatment records, current treatment plans, surgical records, medication use, etc.), lifestyle information (dietary habits, exercise frequency, smoking, drinking, etc.), biological information (such as inflammatory markers, etc.), and physical examination data (such as blood pressure, ECG, sleep monitoring, imaging examinations, etc.). These patients will be followed up long-term (1 month, 6 months, 1 year, and annually thereafter for up to 5 years) to establish a database that meets international standards. Centers meeting the criteria will also retain biological samples, creating a multicenter biobank for elderly CHD patients.
Second, based on the established clinical cohort, a risk prediction model for elderly CHD patients will be developed, including mortality risk, ischemic risk, bleeding risk, etc. Additionally, optimized clinical diagnostic and treatment plans will be formulated to improve the treatment outcomes and quality of life for elderly CHD patients. This research is expected to provide scientific evidence and technical support for the prevention, diagnosis, and treatment of CHD in elderly patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
China Senile Valvular Heart Disease Cohort Study
NCT02865798
The China Valvular Heart Disease Study
NCT03484806
Study on Standard Evaluation System and Optimal Treatment Path of Senile Valvular Heart Disease
NCT05044338
A Registry Study of Biomarkers in Heart Valve Disease
NCT06223906
Valvular Heart Disease Registry Study in Second Affiliated Hospital of ZheJiang University
NCT03011697
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elderly patients with coronary heart disease
1. Establish a cohort and biological sample bank of elderly patients with coronary heart disease
2. Establish a risk prediction model and clinical diagnosis and treatment optimization plan for elderly patients with coronary heart disease
3. Systematically study the multi-dimensional feature spectrum of elderly patients with coronary heart disease
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* This time he was admitted to the hospital due to angina pectoris and other coronary heart disease-related symptoms
③ Conform to the diagnosis of coronary heart disease: meet any one of the following conditions:
1. This admission was performed for coronary angiography, coronary artery CTA confirmed coronary heart disease;
2. Previous clear coronary angiography, coronary artery Coronary heart disease diagnosed by imaging evidence such as CTA evidence;
3. The attending physician according to the patient's symptoms, medical history, myocardial injury markers, electrocardiogram, echo cardiography, myocardial radionuclide imaging, etc. diagnosed coronary heart disease.
④ Informed consent: Participants must be able to understand the content of the study, voluntarily participate in the study, and sign the informed consent form.
Exclusion Criteria
* Unable to cooperate with long-term follow-up: such as patients with severe cognitive impairment or severe mental illness; ③ Non-cardiogenic death within 24 hours after admission.
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fusui Ji, MD
Chief physician and dean of Beijing Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BJ-2024-140
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
BJ-2024-140
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.